Cipla
Cipla is an Indian multinational pharmaceutical company founded in 1935, manufacturing generic and specialty drugs across respiratory, oncology, and chronic disease categories, with operations in India, the US, and Africa serving healthcare providers, hospitals, and patients.
- Company typePublic
- Founded1935
- HeadquartersMumbai, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cipla does
Cipla Ltd. is an Indian multinational pharmaceutical company founded in 1935 and headquartered in Mumbai, operating as India's third-largest pharma firm by revenue with a Rs 28,163 crore (~$3.4B) top line in FY26. The company manufactures and commercializes a diversified portfolio spanning respiratory drugs (flagship brand Foracort crossing Rs 1,000 crore; approved and pipeline complex generics including gVentolin, gAdvair, gSymbicort), oncology products (Nintedanib holding ~50% US share, Lanreotide), chronic disease medications, and consumer healthcare through its Cipla Health subsidiary. Its technology base is anchored in vertically integrated respiratory API manufacturing (India, China, US), inhalation formulation expertise, and emerging capabilities in biosimilars (Kemwell JV), stem cell therapy (Ciplostem with Stempeutics), and CAR-T cell therapy (MedTherapy partnership reducing production timelines from weeks to one day at 70% lower cost).
The business model is anchored in generics manufacturing and branded prescription sales distributed through direct sales forces in India (One India Business contributing 45% of revenue), US generics distribution ($780M, targeting $1B run-rate by FY27), and channel partnerships across Africa (21% YoY growth) and other emerging markets. Regulatory approvals (285 ANDAs/NDAs in the US, US FDA VAI classification for the Goa facility, first AB-rated generic Ventolin from the Fall River plant) serve as primary value drivers, with new CEO Achin Gupta targeting 10% revenue from innovation-led products (biosimilars, complex generics, advanced therapies) within five years. Go-to-market is sales-led through physician detailing and enterprise healthcare relationships, supplemented by strategic distribution partnerships (Eli Lilly for Yurpeak, MannKind for inhaled insulin). The company employs over 22,000 people globally, maintains a net cash position of Rs 10,526 crore, and is publicly listed on Indian exchanges (NSE: CIPLA) with a market capitalization of approximately Rs 1.14 lakh crore.
Cipla firmographics
Firmographics- Name
- Cipla
- Legal name
- Cipla Ltd.
- Website
- https://cipla.com
- Company type
- Public
- Founded year
- 1935
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Cipla is an Indian multinational pharmaceutical company founded in 1935, manufacturing generic and specialty drugs across respiratory, oncology, and chronic disease categories, with operations in India, the US, and Africa serving healthcare providers, hospitals, and patients.
- Ownership category
- akta.pro rank
Cipla industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Chemical and Allied Products Merchant Wholesalers (4246)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Specialty Pharmaceutical Distributors (HLAIAJAB), Biologics & Biosimilars Distributors (HLAIAJAH), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where Cipla is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices7 records
Markets served
Cipla business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generics (India): India contributes nearly 45% of consolidated revenue with strong 15% YoY growth. One India Business surpassed ₹12,500 crore annual revenue milestone growing 15% YoY. Chronic therapies account for over 60% of branded prescription business. Domestic market growth of 14.2% driven by respiratory, diabetes, and cardiovascular segments.
- North America Generics: US revenues declined 16% year-on-year to $780 million in FY26, driven by expected losses from generic Revlimid sales and manufacturing disruptions at partner Pharmathen halting Lanreotide output. Company targets FY27 exit run-rate of $1 billion through planned launches of four respiratory generics (gVentolin, gAdvair, gSymbicort approved/expected) plus three peptide/complex generics.
- Africa and Emerging Markets: Africa business delivered strong 21% YoY growth in Q4 FY26 with 14% growth in dollar terms. The company maintains distribution partnerships and direct presence across African and emerging markets for generics and branded products.
- Innovation Products: Innovation expected to contribute meaningful portion of revenues by Cipla's centenary in about 10 years. Currently ~10% revenue target in five years from innovation-led products including complex generics, biosimilars, stem cell and gene therapies.
- Consumer Healthcare (Cipla Health): Cipla Health subsidiary, led by new CEO Shivam Puri transitioning to One India Business leadership, manages consumer healthcare and wellness portfolio including smoking cessation, pain care, cough and cold, skincare, haircare, and nutrition products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Final dividend of Rs 13 per equity share of face value Rs 2 |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels3 records
Cipla product offering
Product offeringCore offering
Cipla manufactures and distributes a broad portfolio of generic and specialty pharmaceutical products spanning respiratory, oncology, anti-diabetic, cardiovascular, and chronic disease therapies. The company sells branded generics in India through its One India Business, complex generics and inhalation products in the United States via FDA-approved facilities, and essential medicines across Africa and emerging markets, while building an innovation pipeline in biosimilars, stem cell therapy (Ciplostem), and CAR-T cell therapy.
Product overview
Cipla is a pharmaceutical company offering a diversified portfolio of branded generic drugs and specialty medicines across multiple therapy areas. The core offerings include respiratory products (Foracort, gVentolin, gFlovent, gAdvair, gSymbicort), oncology drugs (Nintedanib, Lanreotide), and novel therapies (Ciplostem stem cell therapy, CAR-T cell therapy through partnership with MedTherapy). The company operates through its One India business unit contributing nearly 45% of consolidated revenue, with additional portfolios in consumer healthcare via Cipla Health subsidiary. Strategic focus areas include complex generics, biosimilars (JV with Kemwell Biopharma), and differentiated respiratory products, with generics remaining the mainstay at over 80% of business.
Differentiator
Problem solved
Functional benefit
Brands
- Foracort: Flagship respiratory brand that crossed Rs 1,000 crore revenue milestone during FY26
- Ifosfamide
- Ciplostem
- Yurpeak
- MannKind Partnership
Products and services
- Foracort
Quantifiable outcome
- Foracort flagship respiratory brand crossed ₹1,000 crore revenue milestone during FY26
- +3 more outcomes
Companies that use Cipla
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Cipla technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cipla partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- StempeuticscorePartnership with Stempeutics to launch Ciplostem, a stem-cell therapy for Grade II-III knee osteoarthritis approved by DCGI. Single-dose intra-articular treatment targeting India's 48 million osteoarthritis patients to slow disease progression and improve joint function.
- MedTherapy BiotechcoreTata Sons-backed biotech startup partnered with Cipla for commercialization of CAR-T cell therapy for blood cancer in India. Cipla handles branding and distribution once regulatory approvals are secured. MedTherapy's manufacturing platform reduces CAR-T production from several weeks to one day with 70% cost reduction. Facility planned in Uttar Pradesh targeting 50,000-100,000 patients annually. Therapy currently in Phase II clinical trials in India.
- Eli LillyminorPartnership with Eli Lilly for distribution of Yurpeak (tirzepatide/GLP-1 drug) in India, expanding Cipla's presence in the rapidly growing anti-diabetic and obesity treatment market.
- Kemwell BiopharmacoreJoint venture with Kemwell Biopharma for focused biosimilars pipeline aligned with Cipla's core therapeutic strengths. Plans to add 1-2 products every year over the next 5-6 years targeting the fast-growing biosimilars market for biologic drugs.
- Fennec PharmaceuticalsminorLicensing agreement extension with Fennec Pharmaceuticals for PEDMARK (sodium thiosulfate), extending market exclusivity to at least September 1, 2033. Settlement agreement securing continued market access for pediatric cisplatin-induced hearing loss protection.
- Inzpera HealthsciencesminorCompleted acquisition of Inzpera Healthsciences for Rs 110.65 crore, expanding specialty products portfolio.
Scale indicators13 records
Recent moves7 records
Expansion highlights8 records
Cipla competitors and assessment
Company assessmentDirect peers
- Sun Pharmaceutical Industries: India's largest pharmaceutical company with a comparable diversified generics and specialty portfolio spanning respiratory, chronic disease and complex generics across India, US and emerging markets. Direct competitor in respiratory franchise and US generics.
- Dr. Reddy's Laboratories: Major Indian pharma with parallel exposure to US generics (large ANDA portfolio), complex generics, biosimilars and emerging markets. Direct head-to-head competitor for US generic launches including respiratory.
- Lupin Limited: Indian pharma with strong respiratory franchise (Lupin's Spiriva and generic Advair programs) and US generics presence — directly comparable to Cipla's respiratory differentiation strategy and complex generic pipeline.
- Aurobindo Pharma: Indian pharma heavily exposed to US generics with large ANDAs and injectables portfolio. Competes directly with Cipla in US generic launches, oral solids and emerging market branded generics.
- Zydus Lifesciences (Cadila Healthcare): Indian pharma with biosimilars leadership (similar to Cipla-Kemwell JV), complex generics and US presence. Direct peer in biosimilars ambition and chronic disease domestic franchise.
- Glenmark Pharmaceuticals: Indian pharma with specialty/OTC focus across emerging markets and complex generics in US. Comparable geographic mix and respiratory/allergy portfolio overlap.
- Torrent Pharmaceuticals: Indian pharma with chronic disease focus (cardio, diabetes, CNS) and growing emerging markets presence. Comparable domestic chronic therapy franchise and respiratory/generics strategy.
- Biocon Limited: Indian biopharma with leading biosimilars portfolio and emerging markets focus. Comparable innovation ambition, biosimilars pipeline and partnership-led global commercialization model.
Broad incumbents
- Teva Pharmaceutical Industries: Global generics leader with broad respiratory franchise and large US generics footprint. Overlaps with Cipla in respiratory generics (Advair, Symbicort, ProAir) and complex injectables but operates at much greater global scale.
- Viatris: Global generics and specialty pharma with extensive US distribution and biosimilars pipeline. Direct competitor for US generic launches and biosimilars commercialization overlap.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Cipla social profiles
Digital presenceCipla compliance and trust
Trust signalCompliance1 record
Cipla financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cipla leadership team
Management profileNumber of profiles
Profiles7 records
Cipla subsidiaries and ownership
Company hierarchySubsidiaries5 records
Cipla funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cipla M&A and investment
M&A and investmentM&A6 records
Investments9 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cipla
What does Cipla do?
Cipla manufactures and distributes a broad portfolio of generic and specialty pharmaceutical products spanning respiratory, oncology, anti-diabetic, cardiovascular, and chronic disease therapies. The company sells branded generics in India through its One India Business, complex generics and inhalation products in the United States via FDA-approved facilities, and essential medicines across Africa and emerging markets, while building an innovation pipeline in biosimilars, stem cell therapy (Ciplostem), and CAR-T cell therapy.
Is Cipla a public or private company?
Cipla is a public company. It is classified as public and is currently operating.
When was Cipla founded?
Cipla was founded in 1935. It employs 5,001 to 10,000 people.
Where is Cipla based?
Cipla is headquartered in Mumbai, India, in the Asia region.
How does Cipla make money?
Five revenue lines are on record. Generics (India) is the primary driver. The others are north America Generics, africa and Emerging Markets, innovation Products and consumer Healthcare (Cipla Health).
Who are Cipla's main competitors?
Direct peers on record are Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Lupin Limited, Aurobindo Pharma, Zydus Lifesciences (Cadila Healthcare), Glenmark Pharmaceuticals, Torrent Pharmaceuticals and Biocon Limited. Broad incumbents are Teva Pharmaceutical Industries and Viatris.
Does Cipla have an API?
No public API is recorded for Cipla.
What industry is Cipla in?
Cipla's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.